Melphalan and Hepatitis acute - a phase IV clinical study of FDA data

Summary:

Hepatitis acute is reported as a side effect among people who take Melphalan (melphalan), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Carmustine, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have Hepatitis acute when taking Melphalan. It is created by eHealthMe based on reports of 20,050 people who have side effects when taking Melphalan from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Hepatitis acute?

Hepatitis acute is found to be associated with 594 drugs and 877 conditions by eHealthMe. Check the latest studies of Hepatitis acute.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 30, 2026

20,050 people reported to have side effects when taking Melphalan.
Among them, 21 people (0.1%) have Hepatitis acute.

Could Melphalan cause Hepatitis acute?

Among these 21 people:

How long have people been on Melphalan when they have Hepatitis acute? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Hepatitis acute when taking Melphalan? *

  • female: 15.79 %
  • male: 84.21 %

What is the age of people who have Hepatitis acute when taking Melphalan? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 21.05 %
  • 50-59: 0.0 %
  • 60+: 78.95 %

What are other drugs people take besides Melphalan? *

  1. Carmustine: 10 people, 47.62%
  2. Vancomycin: 6 people, 28.57%
  3. Vitamin C: 4 people, 19.05%
  4. Tramadol: 4 people, 19.05%
  5. Paracetamol: 4 people, 19.05%
  6. Dexamethasone: 2 people, 9.52%
  7. Vitamin K: 1 person, 4.76%
  8. Compazine: 1 person, 4.76%
  9. Dilaudid: 1 person, 4.76%
  10. Cytarabine: 1 person, 4.76%

What are other side effects people have besides Hepatitis acute? *

  1. Weight Increased: 13 people, 61.90%
  2. Venoocclusive Liver Disease (small veins in the liver are obstructed): 13 people, 61.90%
  3. Febrile Neutropenia (fever with reduced white blood cells): 13 people, 61.90%
  4. Abdominal Pain: 13 people, 61.90%
  5. Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 19.05%
  6. Thrombosis (formation of a blood clot inside a blood vessel): 4 people, 19.05%
  7. Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 4 people, 19.05%
  8. Hepatitis B: 2 people, 9.52%
  9. Tenderness (pain or discomfort when an affected area is touched): 1 person, 4.76%
  10. Myocarditis (inflammation of heart muscle myocardium): 1 person, 4.76%

What are the existing conditions these people have? *

  1. Bone Marrow Conditioning Regimen: 14 people, 66.67%
  2. Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 9 people, 42.86%
  3. Skin Infection: 4 people, 19.05%
  4. Neuralgia (pain in one or more nerves): 4 people, 19.05%
  5. Multiple Myeloma (cancer of the plasma cells): 2 people, 9.52%
  6. Primary Amyloidosis (disease that occurs when substances called amyloid proteins build up in your organs): 1 person, 4.76%
  7. Graft Versus Host Disease In Liver (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the liver): 1 person, 4.76%
  8. Febrile Neutropenia (fever with reduced white blood cells): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and have Hepatitis acute?

- Check whether Hepatitis acute is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan:

Hepatitis acute treatments and more:

How severe was Hepatitis acute and when was it recovered:

Expand to all the drugs that have ingredients of melphalan:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Melphalan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis acute:

Browse all the conditions that are associated with Hepatitis acute:


How the study uses the data?

The study uses data from the FDA. It is based on melphalan (the active ingredients of Melphalan) and Melphalan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: